^
Association details:
Biomarker:TP53 wild-type
Cancer:Small Lymphocytic Lymphoma
Drug Class:CD20 inhibitor
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
Excerpt:
Chronic lymphocytic leukemia/Small lymphocytic lymphoma...CLL/SLL without del(17p)/TP53 mutation...First-line therapy…Other recommended regimens…Bendamustine (70 mg/m2 in cycle 1 with escalation to 90 mg/m2 if tolerated) + anti-CD20 monoclonal antibody (not recommended for frail patients).
Secondary therapy:
bendamustine